Terms ending in 2041
Every in-force patent on Juno, Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,851,678 | Methods for Producing Genetically Engineered Cell Compositions and Related Compositions In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 12,006,356 | ANTI-CCT5 Binding Molecules and Chimeric Antigen Receptors Comprising the Same In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 11,471,489 | T Cell Receptors and Engineered Cells Expressing Same In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US D1,124,358 | Menstrual Pain Management Device In force · High confidence | Juno Technologies Inc. | In force | High confidence | |
| US 12,163,952 | Determining Toxicity Risk in CAR T-Cell Therapy In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence | |
| US 12,268,741 | Antibodies and Chimeric Antigen Receptors Specific for Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) In force · High confidence | Juno Therapeutics, Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.